Philadelphia (January 15, 2016) – Oncoceutics, Inc. is pleased to announce that Dr. Joshua Allen, the company’s Vice President for Research and Development, was recently selected by Forbes magazine as an honoree for healthcare in the publication’s 2016 “30 under 30” list. This award recognizes individuals under the age of 30 as “game changers, movers and makers, and brightest minds” in their respective fields.
Dr. Allen was selected for the award by a group of distinguished healthcare experts representing clinical practitioners, biopharmaceutical executives and venture capitalists. His selection was based on his work on Oncoceutics’ lead compound, ONC201, both while a researcher in the lab of Dr. Wafik El-Deiry at the University of Pennsylvania and Penn State University, and while an employee at Oncoceutics.
Dr. Allen received his Ph.D. in Biochemistry and Molecular Biophysics from the University of Pennsylvania and completed a post-doctoral fellowship at the Penn State Hershey Cancer Institute. Since joining Oncoceutics in 2012, Josh has been a key member of the team that has successfully completed a Phase I trial for ONC201 and begun five Phase II trials at four leading cancer centers including the University of Texas MD Anderson Cancer Center, and the Massachusetts General Hospital/Dana Farber Cancer Institute.
“We are delighted that Josh’s discovery and work at Oncoceutics has been recognized by Forbes,” said Wolfgang Oster, CEO, Chairman and co-founder of Oncoceutics. “He is a talented young man with great potential to impact the healthcare field.”
About Oncoceutics
Oncoceutics, Inc. is a clinical-stage drug discovery and development company targeting potent suppressor pathways in human cancer. The first lead compound that entered clinical development from this program is ONC201, a small molecule with an active angular structure and a first-in-class mechanism of action that causes significant anti-tumor activity in a variety of human cancers. The company recently completed a successful Phase I study in solid tumors and has begun Phase II clinical programs in both solid and hematological malignancies. Oncoceutics has been awarded several competitive grants for its development programs with ONC201 and its other candidates in this new class of compounds. In addition, outside interest in the company’s portfolio has resulted in several R&D alliance agreements between Oncoceutics and leading comprehensive cancer centers, including The University of Texas MD Anderson Cancer Center and the Fox Chase Cancer Center. The company has established a robust Intellectual property position, including several issued patents.
Dr. Allen was selected for the award by a group of distinguished healthcare experts representing clinical practitioners, biopharmaceutical executives and venture capitalists. His selection was based on his work on Oncoceutics’ lead compound, ONC201, both while a researcher in the lab of Dr. Wafik El-Deiry at the University of Pennsylvania and Penn State University, and while an employee at Oncoceutics.
Dr. Allen received his Ph.D. in Biochemistry and Molecular Biophysics from the University of Pennsylvania and completed a post-doctoral fellowship at the Penn State Hershey Cancer Institute. Since joining Oncoceutics in 2012, Josh has been a key member of the team that has successfully completed a Phase I trial for ONC201 and begun five Phase II trials at four leading cancer centers including the University of Texas MD Anderson Cancer Center, and the Massachusetts General Hospital/Dana Farber Cancer Institute.
“We are delighted that Josh’s discovery and work at Oncoceutics has been recognized by Forbes,” said Wolfgang Oster, CEO, Chairman and co-founder of Oncoceutics. “He is a talented young man with great potential to impact the healthcare field.”
About Oncoceutics
Oncoceutics, Inc. is a clinical-stage drug discovery and development company targeting potent suppressor pathways in human cancer. The first lead compound that entered clinical development from this program is ONC201, a small molecule with an active angular structure and a first-in-class mechanism of action that causes significant anti-tumor activity in a variety of human cancers. The company recently completed a successful Phase I study in solid tumors and has begun Phase II clinical programs in both solid and hematological malignancies. Oncoceutics has been awarded several competitive grants for its development programs with ONC201 and its other candidates in this new class of compounds. In addition, outside interest in the company’s portfolio has resulted in several R&D alliance agreements between Oncoceutics and leading comprehensive cancer centers, including The University of Texas MD Anderson Cancer Center and the Fox Chase Cancer Center. The company has established a robust Intellectual property position, including several issued patents.
